Effect of Flavopiridol on Radiation-induced Apoptosis of Human Laryngeal and Lung Cancer Cells |
Kim, Su-Zy
(Department of Radiation Oncology, The Catholic University of Korea College of Medicine)
Kwon, Eun-Kyung (Cancer Research Institute, Seoul National University College of Medicine) Lee, Seung-Hee (Cancer Research Institute, Seoul National University College of Medicine) Park, Hye-Jin (Cancer Research Institute, Seoul National University College of Medicine) Wu, Hong-Gyun (Cancer Research Institute, Seoul National University College of Medicine) |
1 | Akilu M, Kindler HL, Donehower RC, Mani S, Vokes EE. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol 2003;14:1270-1273 DOI ScienceOn |
2 | Liu G, Gandara DR, Lara PN Jr, et al. A phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res 2004;10:924-928 DOI |
3 | Jung C, Motwani M, Kortmansky J, et al. The cyclindependent kinase inhibitor flavopiridol potentiates -irradiationinduced apoptosis in colon and gastric cancer cells. Clin Cancer Res 2003;9:6052-6061 PUBMED |
4 | Kim JC, Saha D, Cao Q, Choy H. Enhancement of radiation effects by combined docetaxel and flavopiridol treatment in lung cancer cells. Radiother Oncol 2004;71:213-221 DOI ScienceOn |
5 | Shintani S, Mihara M, Ueyama Y, Matsumura T, Wong DT. Cyclin D1 overexpression associates with radiosensitivity in oral squamous cell carcinoma. Int J Cancer 2001;96:159- 165 DOI ScienceOn |
6 | Schwartz GK, Ilson D, Saltz L, et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001; 19:1985-1992 DOI |
7 | Schwartz GK, O'Reilly E, Ilson D, et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002;20:2157-2170 DOI |
8 | Michalides RJ, van Veelen NM, Kristel PM, et al. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1997;123:497-502 DOI PUBMED ScienceOn |
9 | Datta K, Bellacosa A, Chan TO, Tsichilis PN. Akt is a direct target of the phosphatidylinositol 3-kinase: activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells. J Biol Chem 1996;271:30835-30839 DOI ScienceOn |
10 | Senderowicz AM, Headlee D, Stinson SF, et al. Phase I trial of continuous infusion Flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasm. J Clin Oncol 1998;16:2986-2999 DOI |
11 | Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspases-9 by phosphorylation. Science 1998;282:1318-1321 DOI |
12 | Alesssi DR, Cohen P. Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 1998;8:55- 62 DOI ScienceOn |
13 | Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998;10:262-267 DOI ScienceOn |
14 | Raju U, Nakata E, Mason KA, Kian Ang K, Milas L. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer Res 2003;63: 3263-3267 PUBMED |
15 | Shapiro GI, Supko JG, Patterson A, et al. A phase II trial of cyclin-dependent kinase inhibitor flavopiridol in patients previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 2001;7:1590-1599 |
16 | Yoo SS, Carter D, Turner BC, et al. Prognostic significance of cyclin D1 protein levels in early-stage larynx cancer treated with primary radiation. Int J Cancer 2000;90:22-28 DOI ScienceOn |
17 | Raju U, Ariga H, Koto M, et al. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases. Radiother Oncol 2006; 80:185-191 DOI ScienceOn |
18 | Kim SZ, Wu HG, Shin JH, Park HJ, Kim IA, Kim IH. Enhancement of radiation effects by flavopiridol in uterine cervix cancer cells. Cancer Research and Treatment 2005;37: 191-195 DOI ScienceOn |
19 | Shah MA, Kortmansky J, Motwani M, et al. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 2005;11:3836-3845 DOI ScienceOn |
20 | El-Rayes BF, Gadgeels S, Parchment R, Lorusso P, Philip PA. A phase I study of flavopiridol and docetaxel. Invest New Drugs 2006;24:305-310 DOI ScienceOn |
21 | Newcomb EW, Lymberis SC, Lukyanov Y, et al. Radiation sensitivity of GL261 murine glioma model and enhanced radiation response by flavopiridol. Cell Cycle 2006;5: 93-99 DOI PUBMED ScienceOn |
22 | Kelland LR. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin Investig Drugs 2000;9:2903-2911 DOI ScienceOn |